FLT3 and Hypertension: Furthermore, both drugs suffer from a poor kinase selectivity profile, leading to hand-foot syndrome related to multitargeted tyrosine kinase inhibition (44, 45), overlapping hematopoietic toxicities due to dual inhibition of FLT3 and KIT (36, 46) and high-grade hypertension linked to VEGFR2 inhibition (38, 47).